Glioblastoma Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Glioblastoma stocks.

Glioblastoma Stocks Recent News

Date Stock Title
May 3 DCPH The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine
May 2 CLLS Cellectis announces CFO departure
May 2 CLLS Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
May 2 DCPH Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More
Apr 30 BDRX Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting
Apr 30 DCPH ONO to acquire Deciphera Pharmaceuticals in $2.4B deal
Apr 30 DCPH Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion
Apr 29 CLLS Cellectis GAAP EPS of -$0.64 misses by $0.43, revenue of $1.99M misses by $14.13M
Apr 29 CLLS Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
Apr 29 DCPH Why Is Cancer Focused Deciphera Pharmaceuticals Stock Skyrocketing On Monday?
Apr 29 DCPH Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Apr 29 DCPH Ono Pharmaceutical acquires cancer-focused biopharma Deciphera for $2.4bn
Apr 29 DCPH Deciphera Agrees to $2.4 Billion Buyout Offer From Japan's ONO Pharmaceutical
Apr 29 DCPH Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday
Apr 29 DCPH Deciphera Pharmaceuticals Is Being Acquired and the Stock Soars 72%
Apr 29 DCPH Update: Deciphera Pharmaceuticals to Be Acquired by ONO Pharmaceutical in $2.4 Billion Deal
Apr 29 DCPH Deciphera stock soars after Ono Pharmaceutical’s $2.4B buyout deal
Apr 29 DCPH Deciphera to sell for $2.4B, adding to upswing in biopharma M&A
Apr 29 DCPH UPDATE 2-Japan's Ono to buy US drugmaker Deciphera for $2.4 bln
Apr 29 DCPH Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion
Glioblastoma

Glioblastoma, also known as glioblastoma multiforme (GBM), is the most aggressive cancer that begins within the brain. Initially, signs and symptoms of glioblastoma are non-specific. They may include headaches, personality changes, nausea, and symptoms similar to those of a stroke. Worsening of symptoms often is rapid. This may progress to unconsciousness.The cause of most cases is unclear. Uncommon risk factors include genetic disorders such as neurofibromatosis and Li–Fraumeni syndrome, and previous radiation therapy. Glioblastomas represent 15% of brain tumors. They can either start from normal brain cells or develop from an existing low-grade astrocytoma. The diagnosis typically is made by a combination of CT scan, MRI scan, and tissue biopsy.There is no clear way to prevent the disease. Typically, treatment involves surgery, after which chemotherapy and radiation therapy are used. The medication temozolomide is used frequently as part of chemotherapy. High dose steroids may be used to help reduce swelling and decrease symptoms. It is unclear whether trying to remove all or simply most of the cancer is better.Despite maximum treatment, the cancer usually recurs. The most common length of survival following diagnosis is 12 to 15 months, with fewer than 3% to 5% of people surviving longer than five years. Without treatment, survival is typically three months. It is the most common cancer that begins within the brain and the second most common brain tumor, after meningioma. About 3 per 100,000 people develop the disease a year. It most often begins around 64 years of age and occurs more commonly in males than females. Immunotherapy is being studied.

Browse All Tags